Lipids, lipid complexes and use thereof
The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I), wherein R 1 and R 2 are each and independently selected from the group comprising alkyl; n is any integer between 1 and 4; R 3 is an acyl selected from the group comprising lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II), wherein m is any integer from 1 to 3 and Y − is a pharmaceutically acceptable anion.
1. A method of treating cancer and/or a cardiovascular related disease in a subject, comprising administering to said subject having a cancer and/or a cardiovascular related disease that involves a process selected from the group consisting of angiogenesis and neoangiogenesis an effective amount of a composition comprising a pharmaceutically active component selected from the group consisting of peptides, proteins, oligonucleotides, polynucleotides and nucleic acids; a carrier; and a compound according to formula (I),
wherein R 1 and R 2 are each and independently an alkyl group;
n is any integer between 1 and 4;
R 3 is an acyl group selected from a lysyl, ornithyl, 2,4-diaminobutyryl, histidyl or an acyl moiety according to formula (II),
wherein m is any integer from 1 to 3 and
Y − is a pharmaceutically acceptable anion.
2. The method according to claim 1 , wherein said subject suffers from cancer and wherein said cancer is selected from the group consisting of solid and non-solid tumors.
3. The method according to claim 2 , wherein said cancer is a solid tumor selected from the group consisting of pancreatic cancer, breast cancer, prostate cancer, lung cancer, colon cancer and hepatocellular carcinoma.
4. The method according to claim 1 , wherein said composition is administered to a cell selected from the group consisting of endothelial cells, epithelial cells and tumor cells.
5. The method according to claim 4 , wherein said cells are endothelial cells of the vasculature.
6. The method according to claim 5 , wherein said vasculature is vasculature arising from neoangiogenesis or tumor associated neoangiogenesis.
7. The method according to claim 5 , wherein said vasculature is selected from the group comprising liver vasculature, heart vasculature, kidney vasculature, pancreatic vasculature and lung vasculature.
8. The method according to claim 1 , wherein said pharmaceutically active component is a nucleic acid.
9. The method according to claim 8 , wherein said nucleic acid is a siRNA molecule or a RNAi molecule.
10. The method according to claim 9 , wherein said siRNA molecule reduces expression of CD31 protein expression.
11. The method according to claim 9 , wherein said siRNA molecule reduces CD31 mRNA levels.
12. The method according to claim 9 , wherein said RNAi molecule reduces expression of CD31 protein expression.
13. The method according to claim 9 , wherein said RNAi molecule reduces CD31 mRNA levels.